S6 kinase signaling: Tamoxifen response and prognostic indication in two breast cancer cohorts

Endocrine-Related Cancer

Volumn 22, Issue 3, 2015, Pages 331-343

  Bostner, Josefine ^a   Karlsson, Elin ^a   Eding, Cecilia Bivik ^a   Perez Tenorio, Gizeh ^a   Franzén, Hanna ^a   Konstantinell, Aelita ^a   Fornander, Tommy ^b   Nordenskjöld, Bo ^a   Stål, Olle ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AKT; Endocrine treatment; Estrogen receptor; MTOR; PS6K; S6K1; S6K2

Indexed keywords

ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE; S6 KINASE 1; S6 KINASE 2; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ISOENZYME; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1;

ADJUVANT THERAPY; ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CELL PROLIFERATION; COHORT ANALYSIS; CYTOPLASM; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; IN VITRO STUDY; POSTMENOPAUSE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE; BREAST NEOPLASMS; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; PROGNOSIS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSFECTION;

EID: 84937046056     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0513     Document Type: Article

References (57)

1. Aaltonen K, Amini RM, Landberg G, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H & Blomqvist C 2009 Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Research and Treatment 113 75-82. (doi:10.1007/s10549-008-9908-5)
2. Averous J, Fonseca BD & Proud CG 2008 Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27 1106-1113. (doi:10.1038/sj.onc.1210715)
3. Axelrod MJ, Gordon V, Mendez RE, Leimgruber SS, Conaway MR, Sharlow ER, Jameson MJ, Gioeli DG &Weber MJ 2014 p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks. Cellular Signalling 26 1627-1635. (doi:10.1016/j.cellsig.2014.03.013)
4. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D et al. 2012 Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. Journal of Clinical Oncology 30 2718-2724. (doi:10.1200/JCO.2011.39.0708)
5. Barlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G et al. 2000 Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. Journal of the National Cancer Institute 92 1252-1259. (doi:10.1093/jnci/92.15.1252)
6. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G et al. 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology 27 2630-2637. (doi:10.1200/JCO.2008.18.8391)
7. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F et al. 2012 Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine 366 520-529. (doi:10.1056/NEJMoa1109653)
8. Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ et al. 2014 Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Research 16 R6. (doi:10.1186/bcr3598)
9. Bostner J, Ahnström Waltersson M, Fornander T, Skoog L, Nordenskjöld B & Stål O 2007 Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26 6997-7005. (doi:10.1038/sj.onc.1210506)
10. Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjöld B & Stål O 2013 Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Research and Treatment 137 397-406. (doi:10.1007/s10549-012-2376-y)
11. Boyer D, Quintanilla R & Lee-Fruman KK 2008 Regulation of catalytic activity of S6 kinase 2 during cell cycle. Molecular and Cellular Biochemistry 307 59-64. (doi:10.1007/s11010-007-9584-5)
12. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J & Ramon y Cajal S 2006 Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107 1801-1811. (doi:10.1002/cncr.22195)
13. Cruz R, Hedden L, Boyer D, Kharas MG, Fruman DA & Lee-Fruman KK 2005 S6 kinase 2 potentiates interleukin-3-driven cell proliferation. Journal of Leukocyte Biology 78 1378-1385. (doi:10.1189/jlb.0405225)
14. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ & Joyce MJ 1978 Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Research 38 3352-3364.
15. Fernö M, Borg A & Sellberg G 1986 Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiologica. Oncology 25 171-175. (doi:10.3109/02841868609136398)
16. Fernö M, Stål O, Baldetorp B, Hatschek T, Källström AC, Malmström P, Nordenskjöld B & Rydën S 2000 Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Research and Treatment 59 69-76. (doi:10.1023/A:1006332423620)
17. Filonenko VV, Tytarenko R, Azatjan SK, Savinska LO, Gaydar YA, Gout IT, Usenko VS & Lyzogubov VV 2004 Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors. Experimental Oncology 26 294-299.
18. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C & Blenis J 2004 mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Molecular and Cellular Biology 24 200-216. (doi:10.1128/MCB.24.1.200-216.2004)
19. Goh ET, Pardo OE, Michael N, Niewiarowski A, Totty N, Volkova D, Tsaneva IR, Seckl MJ & Gout I 2010 Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of rapamycin/S6 kinase 2 pathway. Journal of Biological Chemistry 285 17065-17076. (doi:10.1074/jbc.M109.078782)
20. Van Der Hage JA, van den Broek LJ, Legrand C, Clahsen PC, Bosch CJ, Robanus-Maandag EC, van de Velde CJ & van de Vijver MJ 2004 Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. British Journal of Cancer 90 1543-1550. (doi:10.1038/sj.bjc.6601741)
21. Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP, Kasuga M, Nishimoto I & Avruch J 1997 Regulation of eIF-4E BP1 phosphorylation by mTOR. Journal of Biological Chemistry 272 26457-26463. (doi:10.1074/jbc.272.42.26457)
22. Hoang B, Benavides A, Shi Y, Yang Y, Frost P, Gera J & Lichtenstein A 2012 The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. Journal of Biological Chemistry 287 21796-21805. (doi:10.1074/jbc.M111.304626)
23. Ip CK, Cheung AN, Ngan HY & Wong AS 2011 p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene 30 2420-2432. (doi:10.1038/onc.2010.615)
24. Ismail HM 2012 Overexpression of S6 kinase 1 in brain tumours is associated with induction of hypoxia-responsive genes and predicts patients' survival. Journal of Oncology 2012 416927. (doi:10.1155/2012/416927)
25. Ismail HM, Hurd PJ, Khalil MI, Kouzarides T, Bannister A & Gout I 2014 S6 kinase 2 is bound to chromatin-nuclear matrix cellular fractions and is able to phosphorylate histone H3 at threonine 45 in vitro and in vivo. Journal of Cellular Biochemistry 115 1048-1062. (doi:10.1002/jcb.24566)
26. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ et al. 2009 Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of Clinical Oncology 27 5538-5546. (doi:10.1200/JCO.2009.23.3734)
27. Karlsson E, Pérez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, Sgroi DC, Nordenskjöld B, Hallbeck AL & Stål O 2013 The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Research 15 R96. (doi:10.1186/bcr3557)
28. Kawasome H, Papst P, Webb S, Keller GM, Johnson GL, Gelfand EW & Terada N 1998 Targeted disruption of p70s6k defines its role in protein synthesis and rapamycin sensitivity. PNAS 95 5033-5038. (doi:10.1073/pnas.95.9.5033)
29. Kim EK, Kim HA, Koh JS, Kim MS, Kim KI, Lee JI, Moon NM, Ko E & Noh WC 2011 Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Research and Treatment 126 93-99. (doi:10.1007/s10549-010-1315-z)
30. Lane HA, Fernandez A, Lamb NJ & Thomas G 1993 p70s6k function is essential for G1 progression. Nature 363 170-172. (doi:10.1038/363170a0)
31. Lee-Fruman KK, Kuo CJ, Lippincott J, Terada N & Blenis J 1999 Characterization of S6K2, a novel kinase homologous to S6K1. Oncogene 18 5108-5114. (doi:10.1038/sj.onc.1202894)
32. Li PD, Zhang WJ, Zhang MY, Yuan LJ, Cha YL, Ying XF, Wu G & Wang HY 2012 Overexpression of RPS6KB1 predicts worse prognosis in primary HCC patients. Medical Oncology 29 3070-3076. (doi:10.1007/s12032-012-0268-y)
33. Lyzogubov V, Khozhaenko Y, Usenko V, Antonjuk S, Ovcharenko G, Tikhonkova I & Filonenko V 2005 Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer. Experimental Oncology 27 141-144.
34. Maruani DM, Spiegel TN, Harris EN, Shachter AS, Unger HA, Herrero-González S & Holz MK 2012 Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation. Oncogene 31 5073-5080. (doi:10.1038/onc.2011.657)
35. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM & Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics 2006 Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Research and Treatment 100 229-235. (doi:10.1007/s10549-006-9242-8)
36. Miller TW, Balko JM & Arteaga CL 2011 Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. Journal of Clinical Oncology 29 4452-4461. (doi:10.1200/JCO.2010.34.4879)
37. Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM & Paik NS 2008 Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Research and Treatment 110 477-483. (doi:10.1007/s10549-007-9746-x)
38. Pardo OE & Seckl MJ 2013 S6K2: the neglected S6 kinase family member. Frontiers in Oncology 3 191. (doi:10.3389/fonc.2013.00191)
39. Park IH, Bachmann R, Shirazi H & Chen J 2002 Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. Journal of Biological Chemistry 277 31423-31429. (doi:10.1074/jbc.M204080200)
40. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC & Thomas G 2004 S6K1K/K/S6K2K/K mice exhibit perinatal lethality and rapamycin-sensitive 50-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Molecular and Cellular Biology 24 3112-3124. (doi:10.1128/MCB.24.8.3112-3124.2004)
41. Perez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjöld B, Fornander T, Skoog L & Stål O 2011 Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Research and Treatment 128 713-723. (doi:10.1007/s10549-010-1058-x)
42. Reinhard C, Fernandez A, Lamb NJ & Thomas G 1994 Nuclear localization of p85s6k: functional requirement for entry into S phase. EMBO Journal 13 1557-1565.
43. Riemenschneider MJ, Betensky RA, Pasedag SM & Louis DN 2006 AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Research 66 5618-5623. (doi:10.1158/0008-5472.CAN-06-0364)
44. Rosner M & Hengstschlager M 2011 Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR. Oncogene 30 4509-4522. (doi:10.1038/onc.2011.165)
45. Rossi R, Pester JM, McDowell M, Soza S, Montecucco A & Lee-Fruman KK 2007 Identification of S6K2 as a centrosome-located kinase. FEBS Letters 581 4058-4064. (doi:10.1016/j.febslet.2007.07.047)
46. Rutqvist LE & Johansson H 2007 Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncologica 46 133-145. (doi:10.1080/02841860601034834)
47. Savinska L, Skorokhod O, Klipa O, Gout I& Filonenko V 2012 Development of monoclonal antibodies specific to ribosomal protein S6 kinase 2. Hybridoma 31 289-294. (doi:10.1089/hyb.2012.0032)
48. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J & Rozengurt E 2013 Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS ONE 8 e57289. (doi:10.1371/journal.pone.0057289)
49. Sridharan S & Basu A 2011 S6 kinase 2 promotes breast cancer cell survival via Akt. Cancer Research 71 2590-2599. (doi:10.1158/0008-5472.CAN-10-3253)
50. Stål O, Borg A, Fernö M, Källström AC, Malmström P, Nordenskjöld B, South Sweden Breast Cancer Group & Southeast Sweden Breast Cancer Group 2000 ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Annals of Oncology 11 1545-1550.
51. Swedish Breast Cancer Cooperative Group 1996 Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Journal of the National Cancer Institute 88 1543-1549. (doi:10.1093/jnci/88.21.1543)
52. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L et al. 2008 Dose- and scheduledependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. Journal of Clinical Oncology 26 1603-1610. (doi:10.1200/JCO.2007.14.5482)
53. UmSH, Frigerio F, Watanabe M, Picard F, JoaquinM, StickerM, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J et al. 2004 Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 200-205. (doi:10.1038/nature02866)
54. Valovka T, Verdier F, Cramer R, Zhyvoloup A, Fenton T, Rebholz H, Wang ML, Gzhegotsky M, Lutsyk A, Matsuka G et al. 2003 Protein kinase C phosphorylates ribosomal protein S6 kinase bII and regulates its subcellular localization. Molecular and Cellular Biology 23 852-863. (doi:10.1128/MCB.23.3.852-863.2003)
55. Wrange O, Nordenskjold B & Gustafsson JA 1978 Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Analytical Biochemistry 85 461-475. (doi:10.1016/0003-2697(78)90243-9)
56. Yamnik RL & Holz MK 2010 mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor a serine 167 phosphorylation. FEBS Letters 584 124-128. (doi:10.1016/j.febslet.2009.11.041)
57. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ & HolzMK 2009 S6 kinase 1 regulates estrogen receptor a in control of breast cancer cell proliferation. Journal of Biological Chemistry 284 6361-6369. (doi:10.1074/jbc.M807532200)